Investment
Features
FeesSafety
Academy
More
Pluang+

Column bank integrates USDC and USDT stablecoins into core banking for fintechs via single API.

Protocol Fundamentals
18 Sep 2026
Crypto Briefing
View Source
Bullish
Column bank integrates USDC and USDT stablecoins into core banking for fintechs via single API.

Column, a California-chartered bank, has integrated USDC and USDT stablecoins directly into its core banking system, allowing fintech clients to send, receive, and convert stablecoins alongside traditional payments through one API. This system operates 24/7 with immediate fiat settlement and supports multiple blockchains like Solana and Ethereum without needing third-party intermediaries or prefunding. The integration simplifies stablecoin adoption for fintechs such as Brex, Ramp, and Mercury, enabling their business customers to use stablecoins seamlessly. Column also introduced new products including card issuing, global banking accounts, and multicurrency accounts, enhancing fintech capabilities further.

The integration of USDC and USDT stablecoins into Column's core banking infrastructure is the subject here. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Sep 18, 2026 20:01 WIB: out of 50 major cryptocurrencies tradable on Pluang, 46 rose and 3 fell today. Notable movers include UNI (Uniswap) with a price of Rp154.013 and a 1-day change of +25.75%, COTI at Rp383 with +14.15%, and THETA (Theta Network) at Rp3.664 with +12.84%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox's board approved a quarterly cash dividend of $1.36 per share, payable on October 15, 2026, to shareholders recorded by September 30, 2026. This dividend reflects Lennox's ongoing commitment to returning value to its investors. Lennox is a lea...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App